{"product_id":"tb-500","title":"TB-500","description":"\u003ch2\u003eAbout TB-500\u003c\/h2\u003e\n\u003cp\u003eTB-500 is a synthetic peptide corresponding to residues 17 to 23 of thymosin beta 4, the actin binding region of that naturally occurring protein. It is supplied as a lyophilized powder of high analytical purity and is studied in laboratory settings in connection with actin dynamics, cell migration and angiogenic signaling. Peptsche supplies TB-500 strictly as a research material for controlled laboratory investigation.\u003c\/p\u003e\n\n\u003ch3\u003eAvailable Sizes\u003c\/h3\u003e\n\u003cp\u003eTB-500 is supplied as high purity lyophilized powder in a sealed glass vial, accompanied by batch specific analytical documentation.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTB-500 10 mg Vial\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eProduct Specifications\u003c\/h3\u003e\n\u003ctable\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eProduct\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eTB-500 (10 mg) lyophilized powder in sealed glass vial\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eApplication\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eResearch peptide studied in actin binding, cell migration and angiogenesis models\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eAppearance\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSolid white powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eChemical Formula\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eC\u003csub\u003e38\u003c\/sub\u003eH\u003csub\u003e68\u003c\/sub\u003eN\u003csub\u003e10\u003c\/sub\u003eO\u003csub\u003e14\u003c\/sub\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eMolecular Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e889.0 g\/mol\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eCAS Number\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e885340-08-9\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003ePubChem CID\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003ca href=\"https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/62707662\" target=\"_blank\" rel=\"noopener\"\u003e62707662\u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eSequence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAc Leu Lys Lys Thr Glu Thr Gln OH (thymosin beta 4 residues 17 to 23)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eSynonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eTB500, TB 500, TB-500 acetate, Ac-LKKTETQ\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e99% or greater by HPLC, verified per batch\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eStore sealed at 2 to 8 °C, protected from heat, light and moisture\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eRegulatory Status\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eResearch use compound. Not approved for human or veterinary use in any jurisdiction.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch2\u003eWhat is TB-500?\u003c\/h2\u003e\n\u003cp\u003eTB-500 is a short synthetic peptide of seven amino acid residues, acetylated at the N terminus. Its sequence reproduces the actin binding domain of thymosin beta 4, a 43 residue protein present in most mammalian cell types and one of the most abundant intracellular peptides identified in the body.\u003c\/p\u003e\n\u003cp\u003eResearch interest in this fragment arose from work on the parent protein. Thymosin beta 4 functions as the principal actin sequestering molecule in many cells, binding monomeric G actin and regulating its availability for polymerisation. Investigators isolated the binding region to examine whether the shorter sequence retained measurable activity in experimental systems, and TB-500 corresponds to that fragment.\u003c\/p\u003e\n\u003cp\u003eThe published literature on both the parent protein and the fragment is preclinical, comprising in vitro assays and animal models. TB-500 is not an approved therapeutic agent in any jurisdiction. In the United States it appears on the Food and Drug Administration list of bulk drug substances withdrawn from consideration for compounding on the basis of potential immunogenicity and aggregation concerns, and researchers should be aware of that classification.\u003c\/p\u003e\n\n\u003ch2\u003eTB-500 Mechanism of Action (Research Only)\u003c\/h2\u003e\n\u003cp\u003eUnlike compounds that act at a defined cell surface receptor, TB-500 is studied primarily in terms of intracellular protein interaction, specifically its relationship with the actin cytoskeleton.\u003c\/p\u003e\n\n\u003ch3\u003eActin Binding and Cytoskeletal Dynamics\u003c\/h3\u003e\n\u003cp\u003eThe parent protein thymosin beta 4 binds monomeric actin and holds it in a sequestered pool, modulating the balance between free monomer and polymerised filament. The actin binding motif retained in TB-500 is the structural basis for research interest in the fragment, and cytoskeletal reorganisation is the mechanism most consistently examined across published work.\u003c\/p\u003e\n\n\u003ch3\u003eCell Migration Research\u003c\/h3\u003e\n\u003cp\u003eWork published in the FASEB Journal examined directional migration of human umbilical vein endothelial cells in the presence of thymosin beta 4 and reported stimulation of migration in that assay system. Because cell migration depends on coordinated cytoskeletal remodelling, this line of research connects directly to the actin binding mechanism above.\u003c\/p\u003e\n\n\u003ch3\u003eAngiogenic and Tissue Response Signaling\u003c\/h3\u003e\n\u003cp\u003eStudies published in the Journal of Investigative Dermatology examined thymosin beta 4 in experimental wound models and reported accelerated closure in the animal systems used. Subsequent reviews have examined binding modes and downstream biological consequences across a wider set of experimental contexts.\u003c\/p\u003e\n\n\u003ch3\u003eIntegrated Mechanistic Profile\u003c\/h3\u003e\n\u003cp\u003eRecurring themes across the published literature include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eSequestration of monomeric actin and regulation of filament dynamics\u003c\/li\u003e\n\u003cli\u003eInfluence on directional cell migration in endothelial models\u003c\/li\u003e\n\u003cli\u003eInvolvement in angiogenic and tissue response signaling\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eAn important interpretive caution applies to this compound in particular. A substantial portion of the literature examines the full length thymosin beta 4 protein rather than the seven residue fragment sold as TB-500. Findings from the parent protein should not be assumed to transfer to the fragment without direct evidence.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eNote:\u003c\/strong\u003e TB-500 is supplied strictly for research use only. It is intended as an experimental compound for qualified laboratory personnel and is not a drug, food or cosmetic.\u003c\/p\u003e\n\u003cp\u003eTB-500 is supplied exclusively for laboratory research use and is not intended for human or veterinary application.\u003c\/p\u003e\n\n\u003ch2\u003eResearch Applications (Observations from Studies)\u003c\/h2\u003e\n\u003cp\u003eThe following describes areas of published investigation and does not constitute any claim regarding outcomes outside those experimental contexts.\u003c\/p\u003e\n\n\u003ch3\u003eCytoskeletal and Cell Motility Models\u003c\/h3\u003e\n\u003cp\u003eThe most direct application involves in vitro systems examining actin polymerisation state and cellular motility, where the actin binding property can be assessed against measurable endpoints.\u003c\/p\u003e\n\n\u003ch3\u003eEndothelial and Vascular Research\u003c\/h3\u003e\n\u003cp\u003eEndothelial cell models have been used to examine migration and vessel formation dynamics, connecting cytoskeletal mechanism to angiogenic research questions.\u003c\/p\u003e\n\n\u003ch3\u003eTissue Response and Repair Models\u003c\/h3\u003e\n\u003cp\u003eAnimal models examining structural response following induced injury represent an established area of published work for the parent protein, with investigators assessing markers of matrix organisation and cellular recruitment.\u003c\/p\u003e\n\n\u003ch3\u003eComparative Peptide Research\u003c\/h3\u003e\n\u003cp\u003eTB-500 is frequently examined alongside other tissue research peptides in comparative study designs, since its cytoskeletal mechanism differs from compounds acting through nitric oxide or receptor mediated pathways.\u003c\/p\u003e\n\n\u003cp\u003eTB-500 is supplied exclusively for laboratory research use and is not intended for human or veterinary application.\u003c\/p\u003e\n\u003ch2\u003eTB-500 Compared With Related Research Compounds\u003c\/h2\u003e\n\u003cp\u003eThe table below places TB-500 alongside two related compounds in the Peptsche range. It is offered to clarify differences in classification, molecular target and research context. It should not be read as a comparison of clinical performance, safety, or suitability for any application.\u003c\/p\u003e\n\u003ctable\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eCharacteristic\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eTB-500\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\u003ca href=\"\/products\/bpc-157\"\u003eBPC-157\u003c\/a\u003e\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\u003ca href=\"\/products\/wolverine-blend\"\u003eWolverine Blend\u003c\/a\u003e\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eResearch Classification\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSynthetic acetylated seven residue peptide\u003c\/td\u003e\n\u003ctd\u003eSynthetic pentadecapeptide\u003c\/td\u003e\n\u003ctd\u003eTwo component co lyophilized research blend\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003ePrimary Molecular Target\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eMonomeric G actin within the cytoskeleton\u003c\/td\u003e\n\u003ctd\u003eNitric oxide and angiogenic signaling pathways\u003c\/td\u003e\n\u003ctd\u003eNitric oxide signaling and monomeric G actin, addressed by separate components\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eMechanistic Profile\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eActin sequestration and cytoskeletal reorganisation\u003c\/td\u003e\n\u003ctd\u003ePleiotropic activity across several signaling systems\u003c\/td\u003e\n\u003ctd\u003eTwo unrelated pathways, combination not studied in published work\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003ePrimary Research Focus\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCell migration and endothelial models\u003c\/td\u003e\n\u003ctd\u003eTissue integrity, vascular and mucosal models\u003c\/td\u003e\n\u003ctd\u003eVascular and cytoskeletal research in one preparation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eStructural Design\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSeven residues, N terminal acetyl group, free acid C terminus\u003c\/td\u003e\n\u003ctd\u003eFifteen residues, no unnatural residues or modification\u003c\/td\u003e\n\u003ctd\u003eMixture of two peptides, no single formula or CAS number\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eRegulatory Status\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eResearch use compound, not approved for human or veterinary use, and listed by the United States Food and Drug Administration among bulk drug substances withdrawn from consideration for compounding\u003c\/td\u003e\n\u003ctd\u003eResearch use compound, not approved for human or veterinary use\u003c\/td\u003e\n\u003ctd\u003eResearch use blend, neither component approved for human or veterinary use, and the TB-500 component appears on the United States Food and Drug Administration list of bulk drug substances withdrawn from consideration for compounding\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e\n\u003cp\u003eTB-500 is supplied exclusively for laboratory research use and is not intended for human or veterinary application.\u003c\/p\u003e\n\u003ch2\u003eLaboratory Handling and Storage Considerations\u003c\/h2\u003e\n\u003cp\u003eTB-500 should be handled in accordance with institutional laboratory procedures and established practice for research peptides. Maintain storage conditions consistent with product documentation, keeping vials sealed and protected from heat, light and moisture. Record lot numbers, storage conditions and preparation methods in laboratory documentation, and retain certificates of analysis alongside study records to support reproducibility.\u003c\/p\u003e\n\n\u003ch3\u003eLaboratory Safety Considerations\u003c\/h3\u003e\n\u003cp\u003eTB-500 should be handled in the same manner as other research compounds without a fully characterised toxicological profile.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003ePersonal protective equipment:\u003c\/strong\u003e Use appropriate PPE including laboratory coat, nitrile gloves and eye protection.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eEngineering controls:\u003c\/strong\u003e Minimise generation of aerosols or dust. Conduct weighing and transfer procedures using suitable containment.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eExposure prevention:\u003c\/strong\u003e Avoid inhalation, ingestion and contact with skin or eyes. Do not taste or smell the material. Wash hands thoroughly after handling.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Keep containers tightly sealed and protected from light and moisture under the conditions specified.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSpill response:\u003c\/strong\u003e Address spills using appropriate PPE and institutional spill response procedures. Avoid dry sweeping.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eDisposal:\u003c\/strong\u003e Dispose of unused material, consumables and waste in accordance with local regulations and institutional programmes.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eDocumentation:\u003c\/strong\u003e Maintain all lot and handling records. Additional handling guidance is available on request.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eCertificate of Analysis and Quality Assurance\u003c\/h2\u003e\n\u003cp\u003eEvery production lot of TB-500 supplied by Peptsche undergoes analytical evaluation, and a batch specific Certificate of Analysis accompanies each order to support research documentation, quality control and experimental consistency.\u003c\/p\u003e\n\u003cp\u003eEach Certificate of Analysis typically includes:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eIdentity verification\u003c\/strong\u003e using analytical techniques such as mass spectrometry to confirm the molecular characteristics of the material supplied.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePurity analysis\u003c\/strong\u003e performed by high performance liquid chromatography to quantify purity and identify potential impurities.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBatch documentation\u003c\/strong\u003e recording lot number, testing date, analytical methods applied and quality assessment results.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eTraceability information\u003c\/strong\u003e to support laboratory recordkeeping and reproducibility across research workflows.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003ePeptsche works with Janoshik Analytical, an independent testing laboratory, for third party verification of research material quality. Independent testing provides transparency and confidence in product identity, consistency and sourcing, and batch specific documentation can be retained as part of laboratory records and internal quality procedures.\u003c\/p\u003e\n\u003cp\u003eTB-500 is supplied exclusively for laboratory research use and is not intended for human or veterinary application.\u003c\/p\u003e\n\u003ch2\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWhat is TB-500?\u003c\/h3\u003e\n\u003cp\u003eTB-500 is a short synthetic peptide of seven amino acid residues, acetylated at the N terminus, whose sequence reproduces the actin binding domain of thymosin beta 4. Peptsche supplies it as a lyophilized powder of high analytical purity, sealed in a glass vial for controlled laboratory investigation.\u003c\/p\u003e\n\u003ch3\u003eWhat is TB-500 studied for in research?\u003c\/h3\u003e\n\u003cp\u003ePublished investigation is preclinical and spans cytoskeletal and cell motility models, endothelial and vascular research, tissue response models and comparative peptide study designs. A substantial portion of that literature examines the full length thymosin beta 4 protein rather than the seven residue fragment, so findings should not be assumed to transfer without direct evidence.\u003c\/p\u003e\n\u003ch3\u003eHow does TB-500 work in laboratory research?\u003c\/h3\u003e\n\u003cp\u003eTB-500 is studied primarily in terms of intracellular protein interaction rather than activity at a defined cell surface receptor. The retained actin binding motif is the structural basis for research interest, with recurring themes covering sequestration of monomeric actin, influence on directional cell migration in endothelial models and involvement in angiogenic and tissue response signaling.\u003c\/p\u003e\n\u003ch3\u003eHow is the quality of Peptsche TB-500 verified?\u003c\/h3\u003e\n\u003cp\u003eEvery production lot of Peptsche TB-500 is evaluated analytically, with identity confirmed using techniques such as mass spectrometry and purity quantified by high performance liquid chromatography. Peptsche works with Janoshik Analytical, an independent testing laboratory, for third party verification, and a batch specific Certificate of Analysis accompanies each order.\u003c\/p\u003e\n\u003ch3\u003eHow should unopened TB-500 be stored?\u003c\/h3\u003e\n\u003cp\u003eUnopened vials should be stored sealed at 2 to 8 °C, protected from heat, light and moisture. Vials should reach ambient temperature before opening, and lot number, storage conditions and preparation date should be recorded in laboratory documentation so results stay traceable to a batch.\u003c\/p\u003e\n\u003ch3\u003eIs TB-500 intended for human use?\u003c\/h3\u003e\n\u003cp\u003eNo. TB-500 is supplied strictly for laboratory research use only. It is not approved for human consumption, veterinary use, diagnosis, treatment or any medical application.\u003c\/p\u003e\n\u003ch3\u003eWhy do researchers choose Peptsche for TB-500?\u003c\/h3\u003e\n\u003cp\u003ePeptsche supplies TB-500 at 99% or greater purity by HPLC, verified per batch, in a sealed glass vial with batch specific analytical documentation. Independent third party verification and full lot traceability support reproducibility across research workflows.\u003c\/p\u003e\n\u003ch2\u003eScientific References\u003c\/h2\u003e\n\u003col\u003e\n\u003cli\u003eMalinda KM, Sidhu GS, Mani H, Banaudha K, Maheshwari RK, Goldstein AL, Kleinman HK. Thymosin beta4 accelerates wound healing. \u003cem\u003eJournal of Investigative Dermatology\u003c\/em\u003e. 1999;113(3):364 to 368. \u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/10469335\/\" target=\"_blank\" rel=\"noopener\"\u003ehttps:\/\/pubmed.ncbi.nlm.nih.gov\/10469335\/\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli\u003eMalinda KM, Goldstein AL, Kleinman HK. Thymosin beta 4 stimulates directional migration of human umbilical vein endothelial cells. \u003cem\u003eFASEB Journal\u003c\/em\u003e. 1997;11(6):474 to 481. \u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/9194528\/\" target=\"_blank\" rel=\"noopener\"\u003ehttps:\/\/pubmed.ncbi.nlm.nih.gov\/9194528\/\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli\u003eYing Y, Lin C, Tao N, Hoffman RD, Shi D, Chen Z, Gao J. Thymosin beta 4 and Actin: Binding Modes, Biological Functions and Clinical Applications. \u003cem\u003eCurrent Protein and Peptide Science\u003c\/em\u003e. 2023;24(1):78 to 88. \u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/36464872\/\" target=\"_blank\" rel=\"noopener\"\u003ehttps:\/\/pubmed.ncbi.nlm.nih.gov\/36464872\/\u003c\/a\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003ch2\u003eRESEARCH USE ONLY\u003c\/h2\u003e\n\u003cp\u003eThese compounds are NOT intended for human consumption, clinical use, or veterinary applications. We are not affiliated with any pharmaceutical companies or their commercial medications. By placing an order, you certify these materials will be used exclusively for in vitro testing and laboratory experimentation only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabeled as a drug, food or cosmetic.\u003c\/p\u003e","brand":"Peptsche","offers":[{"title":"10mg","offer_id":43752743862335,"sku":"PEP-TB500-10MG","price":50.0,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0675\/7394\/0287\/files\/peptsche_TB500_10mg.png?v=1786901583","url":"https:\/\/peptsche.com\/products\/tb-500","provider":"Peptsche","version":"1.0","type":"link"}